Biospecimen Core

生物样本核心

• 批准号: 10708083
• 负责人: MARK E SHERMAN
• 金额: $ 28.77万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708083
• 关键词: Age; Algorithmic Analysis; Algorithms; Aliquot; Antibodies; Artificial Intelligence; Atypia; Benign; Biological Assay; Biological Markers; Biopsy; Blood; Blood specimen; Breast; Breast Diseases; Breast biopsy; CASP3 gene; CLIA certified; Cancer Burden; Classification; Clinic; Clinical; Clinical Data; Clinical Trials; Collaborations; Cryopreservation; Data Analyses; Distant Metastasis; ERBB2 gene; Evaluation; Evaluation Research; Formalin; Freezing; Gene Mutation; Genetic; Genomic DNA; Histologic; Image Analysis; Immune; Immunohistochemistry; Institution; Knowledge; Link; Lobule; MAGEA3 gene; Malignant - descriptor; Mammaplasty; Mammary Gland Parenchyma; Maps; Metastatic Neoplasm to Lymph Nodes; Methods; Mucin 1 protein; Neoadjuvant Therapy; Neoplasms; Organoids; PKCbeta1; Paraffin Embedding; Pathologic; Pathological Staging; Pathology; Patients; Performance; Plasma; Preparation; Process; Prognostic Marker; Registries; Research; Research Design; Research Project Grants; Residual Cancers; Resource Sharing; Resources; Risk Factors; Risk Reduction; Sampling; Scanning; Serum; Services; Slide; Specimen; Stains; Susceptibility Gene; Technology; Tissue Harvesting; Tissue Microarray; Tissue Sample; Tissues; Translational Research; Vaccine Antigen; Vaccines; Validation; Whole Blood; candidate marker; clinical biomarkers; cohort; cryostat; design; digital; digital imaging; digital pathology; epidemiologic data; experience; high risk; imaging approach; malignant breast neoplasm; mammaglobin; nano-string; neoplastic; patient derived xenograft model; predictive marker; programmed cell death ligand 1; quality assurance; response; software systems; survivin; translational cancer research; translational study; triple-negative invasive breast carcinoma; tumor

PROJECT SUMMARY/ABSTRACT The Biospecimen and Pathology Core of the Mayo Clinic Breast Cancer SPORE provides an expert centralized pathology consultative service and a comprehensive resource of breast tissues, blood and “living samples” for preparation of organoids and patient-derived xenografts, linked to epidemiological and clinical data. The Core also curates clinically derived benign and neoplastic breast tissue samples with detailed clinicopathological evaluation (e.g., stage, histologic features, clinical and emerging biomarker assessments) to establish registries and cohorts for research. Samples collected include fresh, fresh-frozen, cryopreserved and formalin-fixed paraffin embedded specimens from 1) treated or untreated breast cancers with mapped background “benign-adjacent” tissues, 2) lymph node metastases and distant metastases, 3) benign breast disease tissues across the spectrum of pre-neoplasia and 4)“normal” breast tissue harvested from mammoplasty/risk reduction specimens from patients with or without clinical or genetic “high-risk” factors (e.g. known germline BC predisposition gene mutations), as well as blood. The Core performs expert pathological evaluation of research- related histopathological parameters (e.g., atypia in benign breast disease, involution status of breast lobules, histologic subclassification of TNBC, evaluation of tumor response to neoadjuvant therapy, stromal and intratumoral TIL scoring). In addition, the Core performs antibody optimizations as required by the SPORE projects (e.g. PKCBeta1), followed by interpretation and scoring of these immunohistochemical stains, and application of digital image-based approaches (e.g., optimization and interpretation of digital image analysis algorithms with Aperio (Leica) (or HALO (Indica Labs) software systems, high-plex quantitative digital spatial profiling (e.g. Nanostring GeoMX™ platform) for SPORE projects. The Core coordinates with the Mayo Biospecimen Accessioning and Processing (BAP) Shared Resource to store fresh-frozen and cryopreserved specimens and to process blood samples to provide genomic DNA and serum and plasma aliquots; it collaborates with the Mayo Pathology Research Core (PRC) Shared Resource to obtain essential technical tissue-based services including conventional and cryostat tissue sectioning, immunohistochemistry, tissue microarray construction, slide scanning and cytotechnologist assistance for optimizing digital imaging algorithms. Partnering with these institutional shared resources minimizes redundancy of services and capitalizes both on technical experience and state-of-the-art technologies.

项目概要/摘要 梅奥诊所乳腺癌 SPORE 的生物样本和病理学核心提供了专家 集中的病理咨询服务和乳腺组织、血液和“活体”的综合资源 样本”用于制备与流行病学和临床相关的类器官和患者来源的异种移植物 数据。核心还管理临床衍生的良性和肿瘤性乳腺组织样本，并提供详细信息 临床病理学评估（例如分期、组织学特征、临床和新兴生物标志物评估） 建立研究登记处和队列。采集的样品包括新鲜、新鲜冷冻、冷冻保存和 福尔马林固定石蜡包埋的标本来自 1) 经治疗或未经治疗的乳腺癌，并绘制了图谱 背景“良性邻近”组织，2) 淋巴结转移和远处转移，3) 良性乳腺 涵盖肿瘤前期范围的疾病组织和 4) 采集的“正常”乳腺组织 来自具有或不具有临床或遗传“高风险”因素（例如， 已知种系 BC 易感基因突变）以及血液。核心执行专家病理学 评估研究相关的组织病理学参数（例如良性乳腺疾病的异型性、复旧性） 乳腺小叶状态、TNBC 组织学亚分类、肿瘤对新辅助治疗反应的评估 治疗、间质和瘤内 TIL 评分）。此外，Core 还执行抗体优化： SPORE 项目（例如 PKCbeta1）要求的，然后对这些进行解释和评分 免疫组织化学染色，以及基于数字图像的方法的应用（例如，优化和 使用 Aperio (Leica)（或 HALO (Indica Labs) 软件系统解释数字图像分析算法， SPORE 项目的高复杂定量数字空间分析（例如 Nanostring GeoMX™ 平台）。这 与 Mayo 生物样本登记和处理 (BAP) 共享资源进行核心协调来存储 新鲜冷冻和冷冻保存的标本并处理血液样本以提供基因组 DNA 和血清 和血浆等分试样；它与梅奥病理学研究核心（PRC）共享资源合作获得 基本的基于组织的技术服务，包括传统和低温切片机组织切片， 免疫组织化学、组织微阵列构建、载玻片扫描和细胞技术专家协助 优化数字成像算法。与这些机构共享资源合作可以最大限度地减少 服务冗余并利用技术经验和最先进的技术。